A step further in a vaccine for Escherichia coli
- 9 May 2019
- journal article
- editorial
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 19 (6), 565-567
- https://doi.org/10.1016/s1473-3099(19)30069-6
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trialThe Lancet Infectious Diseases, 2019
- A Novel Method of Serum Resistance by Escherichia coli That Causes UrosepsismBio, 2018
- Development and Qualification of an Opsonophagocytic Killing Assay To Assess Immunogenicity of a Bioconjugated Escherichia coli VaccineClinical and Vaccine Immunology, 2017
- Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trialThe Lancet Infectious Diseases, 2017
- Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003–2013World Journal of Urology, 2015
- Extraintestinal PathogenicEscherichia coli, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the FieldThe Journal of Infectious Diseases, 2015
- Fur Is the Master Regulator of the Extraintestinal Pathogenic Escherichia coli Response to SerummBio, 2014
- Role of O-antigen variation in the immune responseTrends in Microbiology, 1995
- Safety And Immunogenicity Of A Polyvalent Escherichia Coli Vaccine In Human VolunteersThe Journal of Infectious Diseases, 1994
- Antibody-Coated Bacteria in the Urine and the Site of Urinary-Tract InfectionThe New England Journal of Medicine, 1974